GlassScriptPhysician profile
Alexandra Smith
NPI 1871948992
$74,759.73
in general payments reported to CMS, 2019-2025
19 companies · $47K in 2025
The $47K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,067 · 2022: $7,601 · 2023: $7,243 · 2024: $11K · 2025: $47K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $41K · Food and Beverage: $12K · Travel and Lodging: $11K · Education: $280 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $41,145.00 |
| Food and Beverage | $12,005.59 |
| Travel and Lodging | $11,461.11 |
| Education | $279.99 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $34,087.11 | 2021-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Teva Pharmaceuticals USA, INC. | $30,632.21 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,806.21 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $1,692.14 | 2021-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $1,361.32 | 2021-2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $1,265.82 | 2021-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $919.31 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $918.78 | 2021-2025 | Invega Sustenna, Invega Trinza |
| Lundbeck LLC | $714.66 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Sunovion Pharmaceuticals INC. | $527.78 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $282.29 | 2024-2025 | Cobenfy |
| Indivior INC. | $194.00 | 2022-2024 | Perseris |
| Axsome Therapeutics, INC. | $137.48 | 2022-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $87.50 | 2021-2024 | Trintellix |
| Janssen Scientific Affairs, LLC | $60.00 | 2025 | Invega Sustenna |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $27.80 | 2022 | |
| Collegium Pharmaceutical, INC. | $16.37 | 2025 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $15.22 | 2025 | Qelbree |
| Noven Therapeutics, LLC | $13.73 | 2025 | Xelstrym, Secuado |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexandra Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.